The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia
Open Access
- 12 September 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Genetics
- Vol. 12 (9), e1006259
- https://doi.org/10.1371/journal.pgen.1006259
Abstract
MicroRNA-22 (miR-22) is emerging as a critical regulator in organ development and various cancers. However, its role in normal hematopoiesis and leukaemogenesis remains unclear. Here, we detected its increased expression during monocyte/macrophage differentiation of HL-60, THP1 cells and CD34+ hematopoietic stem/progenitor cells, and confirmed that PU.1, a key transcriptional factor for monocyte/macrophage differentiation, is responsible for transcriptional activation of miR-22 during the differentiation. By gain- and loss-of-function experiments, we demonstrated that miR-22 promoted monocyte/macrophage differentiation, and MECOM (EVI1) mRNA is a direct target of miR-22 and MECOM (EVI1) functions as a negative regulator in the differentiation. The miR-22-mediated MECOM degradation increased c-Jun but decreased GATA2 expression, which results in increased interaction between c-Jun and PU.1 via increasing c-Jun levels and relief of MECOM- and GATA2-mediated interference in the interaction, and thus promoting monocyte/macrophage differentiation. We also observed significantly down-regulation of PU.1 and miR-22 as well as significantly up-regulation of MECOM in acute myeloid leukemia (AML) patients. Reintroduction of miR-22 relieved the differentiation blockage and inhibited the growth of bone marrow blasts of AML patients. Our results revealed new function and mechanism of miR-22 in normal hematopoiesis and AML development and demonstrated its potential value in AML diagnosis and therapy. We found that miR-22 is transcriptionally activated by PU.1 during monocyte/macrophage differentiation and miR-22 promotes the differentiation via targeting MECOM (EVI1) mRNA and further increasing interaction between c-Jun and PU.1. We also show that miR-22 is a tumor repressor and that PU.1-miR-22-MECOM regulation is involved in AML development; moreover, we demonstrate that reintroduction of miR-22 relieves the differentiation blockage and inhibits the growth of AML bone marrow blasts.Keywords
Funding Information
- The National Natural Science Foundation of China (31171311)
- The National Natural Science Foundation of China (30970616)
- The National Natural Science Foundation of China (81070435)
This publication has 52 references indexed in Scilit:
- A Novel p53/microRNA‐22/Cyr61 Axis in Synovial Cells Regulates Inflammation in Rheumatoid ArthritisArthritis & Rheumatology, 2013
- Macrophage development from HSCs requires PU.1-coordinated microRNA expressionBlood, 2011
- Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemiaProceedings of the National Academy of Sciences of the United States of America, 2010
- High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimatedBlood, 2008
- MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemiaPublished by American Society of Hematology ,2008
- Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminProceedings of the National Academy of Sciences of the United States of America, 2008
- A Minicircuitry Comprised of MicroRNA-223 and Transcription Factors NFI-A and C/EBPα Regulates Human GranulopoiesisCell, 2005
- The Evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell deathThe EMBO Journal, 2000
- Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1Proceedings of the National Academy of Sciences of the United States of America, 1999
- c-Jun Is a JNK-independent Coactivator of the PU.1 Transcription FactorPublished by Elsevier BV ,1999